Literature DB >> 18174483

Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension.

Weiying Dai1, Oscar L Lopez, Owen T Carmichael, James T Becker, Lewis H Kuller, H Michael Gach.   

Abstract

BACKGROUND AND
PURPOSE: The purpose of this study was to examine regional cerebral blood flow (rCBF) in normal cognitive-performing subjects with hypertension (HTN) using continuous arterial spin-labeled MRI. The most common explanation for the effect of blood pressure on cognition is that HTN increases the risk of cerebrovascular disease, and it may increase the risk for Alzheimer disease possibly through small vessel disease, ischemia, oxidative stress, and inflammation. However, few studies to date have examined the rCBF of cognitively normal subjects with HTN in population-based cohorts, and none have used continuous arterial spin-labeled MRI. This is a noninvasive technique that does not require either injections or ionizing radiation and can measure absolute rCBF rates over the entire brain.
METHODS: rCBF was measured at 1.5 T using continuous arterial spin-labeled MRI in 41 cognitively normal subjects who were participating in the Cardiovascular Health Study Cognition Study. A deformable atrophy-corrected registration method was used to warp the rCBF maps to the standard colin27 brain space. Image and cluster-based statistical analyses were performed between subject groups.
RESULTS: Cognitively normal subjects with HTN (n=19) had decreased rCBF in the putamen, globus pallidus, bilaterally, and in the left hippocampus compared with normotensives (n=22). In addition, decreased rCBF was observed in the right and left anterior cingulate gyrus with extension to the subcallosal region, left posterior cingulate gyrus and medial precuneus, left lateral inferior and superior frontal, and inferior parietal, left orbitofrontal, and left superior temporal cortices.
CONCLUSIONS: rCBF is affected in normal subjects with HTN, not only in the subcortical regions, but also in limbic and paralimbic structures. We hypothesize that the HTN creates a vulnerability state for the development of neurodegenerative disorders, especially Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18174483      PMCID: PMC2701215          DOI: 10.1161/STROKEAHA.107.495457

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  38 in total

1.  Apolipoprotein E genotype, vascular risk and early cognitive impairment in an African Caribbean population.

Authors:  R Stewart; C Russ; M Richards; C Brayne; S Lovestone; A Mann
Journal:  Dement Geriatr Cogn Disord       Date:  2001 Jul-Aug       Impact factor: 2.959

2.  Measurement of cerebral perfusion with arterial spin labeling: Part 2. Applications.

Authors:  Gregory G Brown; Camellia Clark; Thomas T Liu
Journal:  J Int Neuropsychol Soc       Date:  2007-05       Impact factor: 2.892

3.  15-year longitudinal study of blood pressure and dementia.

Authors:  I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

4.  Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study.

Authors:  Oscar L Lopez; Lewis H Kuller; James T Becker; Corinne Dulberg; Robert A Sweet; H Michael Gach; Steven T Dekosky
Journal:  Arch Neurol       Date:  2007-03

5.  Reduced cerebral blood flow response and compensation among patients with untreated hypertension.

Authors:  J R Jennings; M F Muldoon; C Ryan; J C Price; P Greer; K Sutton-Tyrrell; F M van der Veen; C C Meltzer
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

6.  Cerebral blood flow in hypertensive patients: an initial report of reduced and compensatory blood flow responses during performance of two cognitive tasks.

Authors:  J R Jennings; M F Muldoon; C M Ryan; M A Mintun; C C Meltzer; D W Townsend; K Sutton-Tyrrell; A P Shapiro; S B Manuck
Journal:  Hypertension       Date:  1998-06       Impact factor: 10.190

7.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study.

Authors:  Ewoud J van Dijk; Monique M B Breteler; Reinhold Schmidt; Klaus Berger; Lars-Göran Nilsson; Matthijs Oudkerk; Andrzej Pajak; Susana Sans; Maria de Ridder; Carole Dufouil; Rebecca Fuhrer; Simona Giampaoli; Lenore J Launer; Albert Hofman
Journal:  Hypertension       Date:  2004-10-04       Impact factor: 10.190

9.  Evaluation of dementia in the cardiovascular health cognition study.

Authors:  Oscar L Lopez; Lewis H Kuller; Annette Fitzpatrick; Diane Ives; James T Becker; Norman Beauchamp
Journal:  Neuroepidemiology       Date:  2003 Jan-Feb       Impact factor: 3.282

10.  Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.

Authors:  G B Karas; P Scheltens; S A R B Rombouts; P J Visser; R A van Schijndel; N C Fox; F Barkhof
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

View more
  67 in total

Review 1.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

2.  Differential effects of age and history of hypertension on regional brain volumes and iron.

Authors:  Karen M Rodrigue; E Mark Haacke; Naftali Raz
Journal:  Neuroimage       Date:  2010-10-20       Impact factor: 6.556

3.  Cerebral Blood Flow Is Associated with Diagnostic Class and Cognitive Decline in Alzheimer's Disease.

Authors:  Wenna Duan; Parshant Sehrawat; Arvind Balachandrasekaran; Ashish B Bhumkar; Paresh B Boraste; James T Becker; Lewis H Kuller; Oscar L Lopez; H Michael Gach; Weiying Dai
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 4.  Potential predictors of hippocampal atrophy in Alzheimer's disease.

Authors:  Vikas Dhikav; Kuljeet Anand
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

5.  Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study.

Authors:  Ihab Hajjar; Peng Zhao; David Alsop; Vera Novak
Journal:  Hypertension       Date:  2010-09-27       Impact factor: 10.190

6.  An inverse association of cardiovascular risk and frontal lobe glucose metabolism.

Authors:  B Kuczynski; W Jagust; H C Chui; B Reed
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

Review 7.  "Boomerang Neuropathology" of Late-Onset Alzheimer's Disease is Shrouded in Harmful "BDDS": Breathing, Diet, Drinking, and Sleep During Aging.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2015-04-25       Impact factor: 3.911

Review 8.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  Imaging cerebral blood flow in the cognitively normal aging brain with arterial spin labeling: implications for imaging of neurodegenerative disease.

Authors:  Charles Lee; Oscar L Lopez; James T Becker; Cyrus Raji; Weiying Dai; Lewis H Kuller; H Michael Gach
Journal:  J Neuroimaging       Date:  2009-03-09       Impact factor: 2.486

10.  Brain imaging findings predict blood pressure response to pharmacological treatment.

Authors:  J Richard Jennings; Matthew F Muldoon; Ellen M Whyte; Joelle Scanlon; Julie Price; Carolyn C Meltzer
Journal:  Hypertension       Date:  2008-11-03       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.